Welcome to our dedicated page for Majestic Ideal SEC filings (Ticker: MJID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Majestic Ideal Holdings Ltd (MJID) aggregates the company’s regulatory reports from its period as a Nasdaq-listed foreign private issuer and through its transition to Ping An Biomedical Co., Ltd with the new ticker PASW. As a foreign private issuer, the company files annual reports on Form 20-F and furnishes current information on Form 6-K under the Securities Exchange Act of 1934.
Among the key filings are the Form F-1 registration statement referenced in a Form 6-K, which underpinned the company’s initial public offering of ordinary shares on the Nasdaq Capital Market, and subsequent Form 6-K reports that describe the underwriting agreement, adoption of governance documents such as the code of business conduct and ethics and committee charters, and the company’s insider trading policy. These documents help investors understand the company’s capital raising and governance framework at the time of its IPO.
The filings page also includes Form 6-K reports covering unaudited first half 2025 financial results, along with Inline XBRL instance and taxonomy extension documents. These materials provide structured financial data for the company’s interim reporting period. Additional Form 6-Ks document corporate actions such as the extraordinary general meeting of shareholders, the approval of the change of company name to Ping An Biomedical Co., Ltd, and the anticipated change in ticker symbol from MJID to PASW.
Further filings detail board and management changes, including resignations and appointments of chief executive officers, the chairperson of the board, the chief financial officer, and independent directors, with the company stating that these resignations were for personal reasons and not due to disagreements with the company or board. On Stock Titan, users can access these filings as they appear on EDGAR and use AI-powered summaries to quickly understand long documents such as the registration statement, Form 20-F annual report, and Form 6-K current reports, as well as review insider trading policies and other governance-related exhibits.
Ping An Biomedical Co., Ltd. has filed to register up to 13,611,800 ordinary shares for resale by an existing shareholder on Nasdaq under the symbol PASW. The company will not receive any proceeds from these sales, which are solely for the selling shareholder’s account.
Ping An operates an apparel supply-chain services business in China through its PRC subsidiary New Brand but is pursuing a major strategic expansion into biopharmaceuticals via planned investments in Future Biotechnology Group. The prospectus highlights extensive risks tied to operating in China, evolving PRC oversight of overseas listings and data security, potential CSRC filing requirements, HFCA Act-related audit risks, and possible cash-transfer constraints from China and Hong Kong.
Additional risks include ambitious performance targets and potentially dilutive share issuances for the Future Biotechnology deal, as well as Nasdaq minimum bid-price and low-price rules that could lead to suspension or delisting if compliance is not regained.
Ping An Biomedical Co., Ltd. entered into securities purchase agreements with accredited investors for a private placement of 100,000,000 ordinary shares at
The shares are being sold in an unregistered offering relying on Section 4(a)(2), Regulation D, and Regulation S exemptions. Investors must be accredited or non‑U.S. persons, and the ordinary shares will carry transfer restrictions and restrictive legends because they are not registered under the U.S. Securities Act.
Ping An Biomedical Co., Ltd. files its annual report on Form 20-F for the year ended September 30, 2025, covering its apparel-focused operations in China conducted through PRC subsidiary New Brand. As of September 30, 2025, 20,500,000 ordinary shares were outstanding.
The company highlights extensive risks tied to operating in mainland China and Hong Kong, including rapid regulatory changes, data and cybersecurity oversight, capital controls, and potential trading prohibitions under the HFCA Act if PCAOB access to auditors is restricted. It notes reliance on PRC and CSRC approvals for overseas listings, and uncertainty around evolving CAC rules.
Business risks include a limited operating history, net losses, going concern and liquidity pressures, heavy dependence on a few major customers, supplier and quality-control risks, rising raw material and labor costs, and seasonality. The report also discloses material weaknesses in internal control over financial reporting, including inadequate segregation of duties and lack of independent directors and an audit committee.
Ping An Biomedical Co., Ltd. reported that it has entered into a series of share purchase agreements with several prominent investors, including Yao Jinbo of 58 Group, Wang Donghui of Amiba Capital, and Li Daxue of Magcloud Group. The company describes these as strategic investments intended to support its long-term development in biopharmaceutical R&D, medical technology, and innovation.
Management highlights that the mix of technology-focused and industry-focused capital reflects confidence in Ping An Biomedical’s ability to commercialize its technologies and scale its healthcare and biomedical businesses. The company plans to deepen its intelligent AI systems and accelerate innovation and commercialization in healthcare and biopharmaceutical technologies while leveraging international capital markets to expand its global influence.
Ping An Biomedical Co., Ltd. filed a Form S-8 to register 4,050,000 ordinary shares (par value US$0.0000625 per share) for issuance under its 2025 Stock Incentive Plan.
The filing includes customary exhibits, such as a Cayman Islands legal opinion on share validity and consents. Cogency Global Inc. is listed as the U.S. agent for service.
Ping An Biomedical Co., Ltd. announced a major leadership transition. In October 2025, the Board accepted the immediate resignations of its Chair (Ms. Yuk Yin Judy Li), Chief Executive Officer and Director (Ms. Lina Jiang), Chief Financial Officer (Ms. Xueyuan Chen), and an independent director (Mr. Taylor Carl Coplen). The company stated each resigned for personal reasons and not due to any disagreement with the company or Board on operations, policies, or practices.
New leadership was appointed effective October 14, 2025. Mr. Pijun Liu was named Chairman, Chief Executive Officer, and Executive Director; Ms. Hongli Yang was appointed Chief Financial Officer; and Mr. Xianzhi Liu joined as an independent director. The filing includes brief professional backgrounds for each appointee.
Majestic Ideal Holdings Ltd. submitted a Form 6-K as a foreign private issuer to provide investors with additional information for the month of September 2025. The report primarily forwards Exhibit 99.1, which announces the company’s unaudited financial results for the first half of 2025.
The filing confirms Majestic Ideal Holdings files annual reports on Form 20-F and lists related Inline XBRL data exhibits. It is signed on behalf of the company by Chairperson of the Board of Directors, Yuk Yin Judy Li, indicating board-level authorization of the submitted information.
Majestic Ideal Holdings Ltd has approved a corporate rebranding and will change its name to Ping An Biomedical Co., Ltd. following shareholder approval at an extraordinary general meeting held on September 12, 2025.
The company’s ordinary shares are expected to begin trading on the Nasdaq Stock Market under the new name and new ticker symbol “PASW” at the open of trading on September 30, 2025. The CUSIP number for the ordinary shares will remain the same, so only the company name and ticker symbol are changing.
Majestic Ideal Holdings Ltd reported the results of its Extraordinary General Meeting held on September 12, 2025 in Hong Kong. As of the August 22, 2025 record date, 20,500,000 Ordinary Shares were outstanding and entitled to vote, and 14,297,969 shares were represented in person or by proxy, equal to 69.57% of the outstanding shares.
Shareholders voted on two items of business, each approved as a special resolution. Proposal 1 received 14,297,631 votes for, 66 votes against, and 272 abstentions. Proposal 2 received 14,297,859 votes for, 66 votes against, and 44 abstentions. The company also filed a related press release as an exhibit.